Artivion, Inc.
$18.16-$0.37 (-2.0%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.0B
- P/E
- 103.7x
- EV / EBITDA
- 18.9x
- Revenue
- $441.3M
- Net margin
- 2.2%
- ROCE
- 6.2%
Price chart
Technical chartScreen technicals →-58.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -21.4%
- 3M
- -35.1%
- 6M
- -19.9%
- 1Y
- -58.8%
- 5Y
- -4.2%
52-week range
Day change -$0.37 (-2.0%) from $19 to $18 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in AORT, bought on each weekday since 2021.
News & filings
What Artivion filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe price is 34.7% below its 200-day average, and the 50-day average is below the 200-day.
Strengths (1)
- Operating margin of 6.1% against a peer median of 2.0%.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
Read moreShow less
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
- Sector
- Healthcare
- Shares outstanding
- 47.8M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.0B
- P/E
- 103.7x
- P/B
- 2.3x
- EV / EBITDA
- 18.9x
- EV / Sales
- 2.7x
- P/S
- 2.3x
- 52-week high
- $47.18
- 52-week low
- $18.16
Profitability
- Operating margin
- 6.1%
- Net margin
- 2.2%
- EBITDA margin
- 14.5%
- ROE
- 2.2%
- ROCE
- 6.2%
- ROA
- 1.1%
- Asset turnover
- 0.50
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $441.3M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 13.6%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 12.0%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -173.1%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $839.0k
Solvency
- Current ratio
- 3.53
- Debt / Equity
- 0.57
- Debt / Assets
- 0.29
- CFO / Net profit
- 4.09
- Cash / Market cap
- 6.4%
Where the revenue went
Of every $100 of FY2025 revenue, $2 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $157.1M |
| Revenue | Gross profit | $284.2M |
| Gross profit | Research and development | $31.0M |
| Gross profit | Selling, general and administrative | $226.5M |
| Gross profit | Other operating expenses | $10.0k |
| Gross profit | Operating income | $26.7M |
| Operating income | Pretax income | $14.8M |
| Operating income | Interest and other expense | $12.0M |
| Pretax income | Tax and other | $5.0M |
| Pretax income | Net income | $9.8M |
Revenue and net profit
Revenue grew 13.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $313.8M | -$19.2M |
| FY2023 | $354.0M | -$30.7M |
| FY2024 | $388.5M | -$13.4M |
| FY2025 | $441.3M | $9.8M |
Cash flows
FY2025: $39.9M from operations, $839.0k free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$5.2M | -$15.9M |
| FY2023 | $18.8M | $9.1M |
| FY2024 | $22.2M | $11.0M |
| FY2025 | $39.9M | $839.0k |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $441.3M+13.6%1Y
- EBITDA
- $63.8M+25.2%1Y
- Net profit
- $9.8M
- Cash from operations
- $39.9M+79.3%1Y
- Free cash flow
- $839.0k-92.4%1Y
- Revenue CAGR, 3Y
- 12.0%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $441.3M | $63.8M | $9.8M | $839.0k | 2.2% | +13.6% | -173.1% |
Monthly returns
Month-by-month returns of AORT across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $884.8M |
| Current assets | $358.1M |
| Non-current assets | $526.7M |
| Liabilities | $436.6M |
| Current liabilities | $101.6M |
| Non-current liabilities | $335.0M |
| Equity | $448.2M |
| Paid-in capital | $516.6M |
| Retained earnings | -$51.5M |
| Treasury stock | $14.7M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; AORT highlighted.
P/E against peers
AORT trades at 103.7x earnings against a peer median of -2.7x.
Not shown (no positive earnings and no EV / Sales): Corvus Pharmaceuticals, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Artivion, Inc.AORTthis company | $1.0B | 103.7x | 2.3x | 2.2% | 18.9x |
| Collegium Pharmaceutical, Inc.COLL | $1.1B | 16.9x | 3.5x | 20.8% | 4.1x |
| CONMED CorporationCNMD | $1.1B | 22.5x | 1.0x | 4.6% | 10.5x |
| Azenta, Inc.AZTA | $1.1B | -18.9x | 0.6x | -3.2% | 20.8x |
| The Pennant Group, Inc.PNTG | $1.0B | 35.4x | 3.1x | 8.9% | 24.4x |
| QuidelOrtho CorporationQDEL | $1.0B | -0.9x | 0.5x | -58.9% | -7.7x |
| EyePoint, Inc.EYPT | $1.0B | -4.4x | 3.4x | -75.8% | -4.1x |
| Corvus Pharmaceuticals, Inc.CRVS | $985.5M | -64.5x | 16.1x | -25.0% | -22.9x |
| InnovAge Holding Corp.INNV | $977.3M | -32.2x | 4.2x | -12.9% | -102.4x |
| Peer median | — | -2.7x | 3.3x | -8.1% | -0.0x |
Year-to-date ROI
AORT since 1 January, against earlier years.
Historical volatility
AORT's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 2.0% |
| FY2023 | -2.4% |
| FY2024 | 10.0% |
| FY2025 | 6.1% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $441.3M |
| Cost of revenueCost Of Revenue | $157.1M |
| Gross profitGross Profit | $284.2M |
| Operating expensesOperating Expense | $257.5M |
| Research and developmentResearch And Development | $31.0M |
| Selling, general and administrativeSelling General And Administration | $226.5M |
| Total expensesTotal Expenses | $414.6M |
| Operating incomeOperating Income | $26.7M |
| Interest and other | |
| Pretax incomePretax Income | $14.8M |
| TaxTax Provision | $5.0M |
| Net incomeNet Income | $9.8M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $884.8M |
| Current assetsCurrent Assets | $358.1M |
| Non-current assetsTotal Non Current Assets | $526.7M |
| LiabilitiesTotal Liabilities Net Minority Interest | $436.6M |
| Current liabilitiesCurrent Liabilities | $101.6M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $335.0M |
| EquityTotal Equity Gross Minority Interest | $448.2M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $39.9M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $39.9M |
| Net income, continuing operationsNet Income From Continuing Operations | $9.8M |
| Depreciation and amortisationDepreciation And Amortization | $22.5M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $22.5M |
| Stock-based compensationStock Based Compensation | $24.4M |
| Deferred taxDeferred Tax | $40.0k |
| Deferred income taxDeferred Income Tax | $40.0k |
| Operating gains and lossesOperating Gains Losses | -$4.3M |
| Asset impairmentAsset Impairment Charge | $4.9M |
| Change in working capitalChange In Working Capital | -$22.2M |
| Other non-cash itemsOther Non Cash Items | $4.8M |
| Investing cash flowInvesting Cash Flow | -$42.0M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$42.0M |
| Capital expenditureCapital Expenditure | -$39.0M |
| Capital expenditure (reported)Capital Expenditure Reported | -$39.0M |
| AcquisitionsPurchase Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | — |
| Sale of investmentsSale Of Investment | — |
| Net investment purchases and salesNet Investment Purchase And Sale | — |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Other investing changesNet Other Investing Changes | -$3.0M |
| Financing cash flowFinancing Cash Flow | $11.3M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $11.3M |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | -$2.5M |
| Net debt issuedNet Issuance Payments Of Debt | -$2.5M |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | -$2.3M |
| Net short-term debt issuedNet Short Term Debt Issuance | -$2.3M |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | -$210.0k |
| Net long-term debt issuedNet Long Term Debt Issuance | -$210.0k |
| Net common stock issuedNet Common Stock Issuance | $0.00 |
| Common stock repurchasedCommon Stock Payments | $0.00 |
| Share buybacksRepurchase Of Capital Stock | $0.00 |
| Stock options exercisedProceeds From Stock Option Exercised | $13.1M |
| Other financing chargesNet Other Financing Charges | $670.0k |
| Change in cashChanges In Cash | $9.1M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 232.0% |
| Cash at the start of the yearBeginning Cash Position | $53.5M |
| Cash at the end of the yearEnd Cash Position | $64.9M |
| Free cash flowFree Cash Flow | $840.0k |
Learn while you research
Academy chapters picked for Artivion, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Valuation Multiples ExplainedThis stock trades at a P/E of 103.7, learn when high multiples are justified.6 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read